Rasheed Abdulraheem

Mr. Rasheed Abdulraheem


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
NRNasim Rezaee
Nasim Rezaee
EHEugene Hone
Eugene Hone
HSHamid R. Sohrabi
Hamid R. Sohrabi
RARasheed Abdulraheem
Rasheed Abdulraheem
SJStuart Johnson
Stuart Johnson
BFBinosha Fernando
Binosha Fernando
Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with poorly understood pathology. Elevated tau, phospho-tau and mitochondrial dysfunction are significantly correlated with an increased risk of AD and are therefore targets for disease-modifying therapy. In this study, we examined the effects of polyphenolic extracts from six different varieties of sorghum: Shawaya short black-1 (Black), IS1311C (Brown), QL33/QL36 (Red), B923296 (Red), QL12 (White), and QL33 (Red) on the attenuation of beta amyloid-induced phospho-tau levels, total tau levels, and mitochondrial dysfunction in neuronal cells. Method: Tau proteins (231 (pT231), Serine- 199 (pS199), and total tau proteins (T-tau)) were detected and quantified using sandwich ELISA kits, while mitochondrial dysfunction was measured in terms of mitochondrial membrane potential (Δψm) and adenosine triphosphate (ATP) levels. Results: Almost all varieties of the sorghum extracts reduced the beta amyloid-induced pS199 and pT231 levels (p ≤ 0.05). The optimum concentration of QL33/QL36 (1000 µg/mL), QL12 (2000 µg/mL), and QL33 (2000 µg/mL) strongly attenuated the phospho-tau level. Sorghum IS1311C (750 µg/mL) showed the highest Δψm reduction (39.8%), whereas QL33 (2000 µg/mL) most strongly improved the ATP level (37.7%) (p ≤ 0.01). For both Δψm and ATP assays, the least activity was observed in sorghum B923296 at 21% and 25.5%, respectively (p ≤ 0.01). Conclusions: The polyphenol extracts from sorghum attenuated the tau toxicity and Aβ-induced mitochondrial dysfunction in a variety- and dose-dependent manner and made a promising disease-modifying agent against AD. However, extensive research is needed to validate the efficacy of the sorghum extracts prior to animal and clinical studies.

1 December 2024 in Alzheimer's & Dementia
Verified
Journal Article
Open access
RARasheed Abdulraheem
Rasheed Abdulraheem
PBPrashant Bharadwaj
Prashant Bharadwaj
ZLZhaoyu Li
Zhaoyu Li
RCRanil Coorey
Ranil Coorey
SJStuart Johnson
Stuart Johnson
WFWarnakulasuriya Mary Ann Dipika Binosha Fernando
Warnakulasuriya Mary Ann Dipika Binosha Fernando
Background: Accumulation of amyloid beta 42 (Aβ42) senile plaques is the most critical event leading to Alzheimer’s disease (AD). Currently approved drugs for AD have not been able to effectively modify the disease. This has caused increasing research interests in health beneficial nutritious plant foods as viable alternative therapy to prevent or manage AD. Sorghum bicolor presents strong antioxidants, anticancer, anti‐inflammatory and antidiabetic properties. However, there is no published data on how this widely available and cost‐effective food could benefit people living with AD.Method: Polyphenols were extracted from three Sorghum varieties with black, reddish‐brown, and red pericarp. The individual polyphenols compounds were identified using an Agilent 1290 infinity 2 UHPLC system coupled to an Agilent 6475 LC‐QQQ LC‐MS/MS. The polyphenol extracts were screened using in‐silico, MC65 cell and Caenorhabditis elegans AD models. The activities of the extracts against Aβ42 aggregation were analyzed using molecular docking, fluorescence, toxicity, and healthspan assays.Result: Through the application of molecular docking, polyphenols extracted from Sorghum bicolor grains were identified for their potential to inhibit Aβ42 aggregation. Positive interactions were observed between the polyphenols and Aβ42. Cell studies indicated increased viability of MC65 cells, possibly attributed to the inhibition of Aβ42 aggregation. In the Alzheimer’s disease model of Caenorhabditis elegans, enhanced body bending, and pharyngeal pumping were observed compared to controls, suggesting a reduction in pathology. The order of activities was found to be red pericarp < reddish‐brown pericarp < black pericarp sorghum.Conclusion: The polyphenol extracts from black pericarp Sorghum bicolor grain could be a candidate ingredient in the development of complementary dietary supplement for AD therapy. Future investigation include lifespan, and fluorescence imaging to unravel the mechanisms underlying the observed health benefits prior to study in AD animal models.

30 June 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
RARasheed Abdulraheem
Rasheed Abdulraheem
RMRalph Martins
Ralph Martins
RKRajapandiyan Krishnamoorthy
Rajapandiyan Krishnamoorthy
MAMohammad A. Alshuniaber
Mohammad A. Alshuniaber
Prashant BharadwajPrashant Bharadwaj
Prashant Bharadwaj
BFBinosha Fernando
Binosha Fernando
Background/Objective: Accumulation of amyloid-beta (Aβ) senile plaques in the human brain is a major hallmark of Alzheimer’s disease (AD), which manifests as progressive decline in memory and cognitive functions and currently lacks effective disease-modifying therapies. Emerging evidence demonstrates that polyphenol-rich plant foods are potential complementary therapies for AD. Methods: In this study, we investigated crude polyphenol extracts (CPEs) and purified polyphenol extracts (PPEs) from three sorghum genotypes for their ability to inhibit Aβ42-induced toxicity in MC-65 cells. Thioflavin T fluorescence, cell viability, mitochondrial function, oxidative stress assays, and Western blotting, along with RNA sequencing and computational analyses, were used to characterise both functional and transcriptomic responses of the cells to polyphenol treatments. Results: CPEs and PPEs inhibited Aβ42 aggregation by 67–76% and significantly reduced Aβ oligomer species. The extracts increased cell viability against Aβ-induced toxicity by more than 70%, decreased intracellular oxidative stress, and enhanced mitochondrial activity by over 80%. Transcriptomic profiling revealed differential modulation of genes associated with ferroptosis and MAPK/NF- κB signalling pathways, indicating regulation of inflammatory and oxidative-stress responses are mechanisms underlying the observed neuroprotection. Conclusions: This study demonstrates that polyphenol extracts from black and red sorghum genotypes exert strong multitarget neuroprotection against Aβ42 toxicity in MC-65 cells. These findings support further evaluation of sorghum-derived polyphenols as complementary therapeutic candidates for AD, with in vivo studies required to establish efficacy and translational potential.